Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Multicenter Observational Study of the Safety and Effectiveness of Tenecteplase (rhTNK-tPA) for Acute Ischemic Stroke Across Different Transfer Pathways

NCT07897955 is registered in ClinicalTrials.gov with Fujian Medical University Union Hospital as lead sponsor.

NCT NCT07897955 Not yet recruiting Observational 2,000 participants (estimated) Started 2027 6 sites

Follow this trial by email Email me the PDF

Get the NCT07897955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started April 2027. Observational study, 2,000 participants (estimated). Lead sponsor Fujian Medical University Union Hospital; China. Primary measure: Modified Rankin Scale Score at 90 Days.

How it compares

768 similar trials: same condition (Ischemic Stroke) and phase

Enrollment

This trial
2,000
Middle half
100 to 1,000
Median
300
Trials with a value
755

Months from start to completion

This trial
33
Middle half
19 to 60
Median
34.1
Trials with a value
763

Sites

This trial
6
Middle half
1 to 1
Median
1
Trials with a value
695
Posted results or a linked paper 40% 311 of 768 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Multicenter Observational Study of the Safety and Effectiveness of Tenecteplase (rhTNK-tPA) for Acute Ischemic Stroke Across Different Transfer Pathways
Lead sponsor
Fujian Medical University Union Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
April 1, 2027
Completion date
December 30, 2029
Enrollment
2,000 (estimated)
Sites
6

Conditions

MeSH condition names; the registry's own terms follow.

Ischemic Stroke

Registry terms: acute ischemic stroke

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Observational
Sites
6
Countries
China
Lead sponsor
Fujian Medical University Union Hospital

Arms

As registered; 1 arm.

Registered arms
Arm Type Interventions
Patients Treated With Tenecteplase tenecteplase
Show registry wording

Patients with acute ischemic stroke who receive intravenous tenecteplase as part of routine clinical care and are followed for 90 days. Treatment and transfer decisions are made by the treating physicians and are not assigned by the study protocol.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Modified Rankin Scale Score at 90 Days 90 days after tenecteplase administration (±7 days)

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Tenecteplase 1 Orange Book patent
    • US 5385732; expires June 2, 2014; assignee Genentech

Lead sponsor's other trials

Fujian Medical University Union Hospital, most recent start first.

Similar trials

Same condition (Ischemic Stroke) and phase, most recent start first.